MEDIPOST Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 11, 2022 at 01:48 am
Share
MEDIPOST Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 16,323.5 million compared to KRW 13,231.61 million a year ago. Net income was KRW 15,998.61 million compared to net loss of KRW 29.23 million a year ago. Basic earnings per share from continuing operations was KRW 991 compared to basic loss per share from continuing operations of KRW 2 a year ago. Diluted earnings per share from continuing operations was KRW 991 compared to diluted loss per share from continuing operations of KRW 2 a year ago. Basic earnings per share was KRW 991 compared to basic loss per share of KRW 2 a year ago.
For the nine months, sales was KRW 4,085.9 million compared to KRW 1,657.52 million a year ago. Net loss was KRW 1,886.6 million compared to KRW 5,338.86 million a year ago. Basic loss per share from continuing operations was KRW 117 compared to KRW 333 a year ago. Diluted loss per share from continuing operations was KRW 117 compared to KRW 333 a year ago. Basic loss per share was KRW 117 compared to KRW 333 a year ago.
MEDIPOST Co., Ltd. is a Korea-based company engaged in the biotechnology business. The Company mainly operates cord blood banks. Its cord blood banks consist of public cord blood bank, which provides resource to anyone who may need to undergo hematopoietic stem cell transplantation (HSCT) as a result of blood-related diseases, such as leukemia or aplastic anemia, as well as family cord blood bank, which provides services for storing newbornâs cord blood exclusively for familyâs use. It also involves in the provision of stem cell drugs, which are used for recovery of knee articular cartilage and others, distribution of healthcare food and natural cosmetics, as well as provision of healthcare services.
MEDIPOST CO., LTD. 
